Biochemical recurrence (BCR) is a clinical challenge in prostate cancer (PCa) patients as recurrence localization guides subsequent therapies. The use of positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) presents better accuracy than standard imaging practice.